None listed
Conditions
Interventions
Drug : Participants in the experimental group are prescribed Granpherol 400 IU bid for 8 weeks and participants in Control do not get any management for 8 weeks
Sponsors
Ajou University Hospital
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: - burning mouth syndrome patients who have sustained orofacial pain more than 3 months without any substantial abnormalities in the oral cavity - post-menopausal females - participants who agreed to enroll this clinical trial
Exclusion criteria
Exclusion criteria: - Participants who have hypersensitivity on Grandferol 400IU - Hypertension patients - Participants who have history of asthma, rash, uticaria - Participants taking vitamin A or vitamin K or having thrombolism - Participants taking oral anticoagulant - Participants taking Orlistat or mineral oil - Hyperproteinemina, hypercholesterolemia or pancreatitis patients who had abnormal lipid metabolism - Participants with lipid overload - Participants with malignant tumor, history of radiation therapy or radiation isotope therapy in head and neck area - Participants taking steroid, immune suppressant, or cytotoxic drug - Participants with uncontrolled diabetes or thyroid disorder - Participants with coagulation problem - Participants with liver diseases - Participants who are unable to communicate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| extents of oxidative stress in saliva and serum (8-hydroxy-2’-deoxyguanosine (8-OHdG), total antioxidant capacity (TAC), uric acid) | — |
Secondary
| Measure | Time frame |
|---|---|
| degree of pain (Visual Analog Scale, Oral Health Impact Profile-49, McGuill questionnare) | — |
Countries
Korea, Republic of
Contacts
Public ContactJeong-Hyun Kang
Ajou University
Outcome results
None listed